Published in Immunol Cell Biol on May 24, 2011
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity. Front Immunol (2013) 0.89
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83
IL-2 repositioned. Immunol Cell Biol (2011) 0.75
Identification of a cytotoxic form of dimeric interleukin-2 in murine tissues. PLoS One (2014) 0.75
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87
Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity (2003) 5.52
Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med (2006) 3.65
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Growth factors in the extracellular matrix. FASEB J (1997) 2.71
Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity (2007) 2.71
The role of heparan sulphate in inflammation. Nat Rev Immunol (2006) 2.51
IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med (2001) 2.29
Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol (2005) 2.28
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Mammalian heparanase: what is the message? J Cell Mol Med (2007) 1.91
Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem (1995) 1.61
Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem (2004) 1.43
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Interleukin-2 expression by a subpopulation of primary T cells is linked to enhanced memory/effector function. Immunity (1999) 1.36
Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol (1999) 1.26
Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol (2006) 1.24
The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun (2008) 1.24
Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine (2000) 1.23
Human platelet heparanase: purification, characterization and catalytic activity. Biochem J (1998) 1.11
Relationships between glycosaminoglycan and receptor binding sites in chemokines-the CXCL12 example. Carbohydr Res (2008) 1.11
Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem (2006) 1.08
Regulation of T cell homeostasis by heparan sulfate-bound IL-2. J Immunol (1999) 1.04
Immunocytochemical localization of endogenous anti-thrombin III in the vasculature of rat tissues reveals locations of anticoagulantly active heparan sulfate proteoglycans. J Histochem Cytochem (1994) 1.02
Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol (2003) 1.01
The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J Biol Chem (2006) 1.01
IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol (1988) 0.99
Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol (2008) 0.96
Propagation and control of T cell responses by heparan sulfate-bound IL-2. J Immunol (2003) 0.96
Interactions between interleukin-2-activated lymphocytes and vascular endothelium: binding to and migration across specialized and non-specialized endothelia. Immunology (1992) 0.95
Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis? Anticancer Agents Med Chem (2008) 0.94
Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem (2002) 0.93
Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis (2004) 0.91
Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology (2000) 0.90
Interleukin-2 promotes angiogenesis by activation of Akt and increase of ROS. J Microbiol Biotechnol (2008) 0.89
Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology (1996) 0.87
Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro. Am J Respir Cell Mol Biol (1992) 0.87
Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci (2007) 0.87
Perlecan: a major IL-2-binding proteoglycan in murine spleen. Immunol Cell Biol (2007) 0.86
Functional role for the myeloid differentiation antigen CD14 in the activation of human monocytes by IL-2. J Immunol (1997) 0.84
Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation. Exp Clin Transplant (2004) 0.82
Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro. Inflammation (1996) 0.81
Proteoglycan form of colony-stimulating factor-1 (proteoglycan-100). Stimulation of activity by glycosaminoglycan removal and proteolytic processing. J Immunol (1995) 0.80
Interleukin-2 modulates the responsiveness to angiotensin II in cultured vascular smooth muscle cells. Atherosclerosis (1997) 0.79
Interleukin-2 induces increased platelet-endothelium interactions: a potential mechanism of toxicity. J Lab Clin Med (1996) 0.79
Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells. Life Sci (2005) 0.78
How interleukin-2 can affect human fibroblasts behaviour. Pathol Res Pract (1994) 0.77
West Nile virus-associated encephalitis in recipients of renal and pancreas transplants: case series and literature review. Clin Infect Dis (2004) 1.84
Regional manifestations and control of the immune system. FASEB J (2002) 1.38
New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation (2005) 1.06
Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant (2002) 0.99
Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol (2003) 0.94
Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation (2008) 0.92
Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation (2011) 0.90
Perlecan: a major IL-2-binding proteoglycan in murine spleen. Immunol Cell Biol (2007) 0.86
Greater early pancreas graft loss in women compared with men after simultaneous pancreas-kidney transplantation. Clin Transplant (2005) 0.84
Presumptive serum sickness as a complication of rabbit-derived antithymocyte globulin immunosuppression. Arthritis Rheum (2009) 0.84
Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation (2012) 0.83
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Improved islet yields from Macaca nemestrina and marginal human pancreata after two-layer method preservation and endogenous trypsin inhibition. Am J Transplant (2003) 0.81
Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis. Expert Rev Anti Infect Ther (2014) 0.80
Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant. Transplantation (2008) 0.80
Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant (2011) 0.78
Influence of interleukin-2 deficiency on the generation of autoimmune B cells. J Autoimmun (2007) 0.77
Maternal microchimerism leads to the presence of interleukin-2 in interleukin-2 knock out mice: implications for the role of interleukin-2 in thymic function. Cell Immunol (2007) 0.77
Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus. Clin Transplant (2010) 0.77
Extended donor iliac arterial patch for vascular reconstruction during pancreas transplantation. Am J Transplant (2004) 0.76
Loss of renal allografts secondary to Candida vascular complications in two recipients from the same donor. Case Rep Transplant (2012) 0.75
Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues. Adv Exp Med Biol (2015) 0.75
Acute transverse myelitis and paralysis in a kidney-pancreas recipient. Transpl Int (2009) 0.75